Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRUG NASDAQ:ORIC NASDAQ:PROK NASDAQ:VERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRUGBright Minds Biosciences$33.63-0.4%$28.00$0.94▼$79.02$236.76M-6.0737,435 shs43,115 shsORICOric Pharmaceuticals$10.12+1.5%$9.94$3.90▼$14.67$862.43M1.691.21 million shs942,341 shsPROKProKidney$2.82+1.8%$1.78$0.46▼$7.13$825.41M1.7638.15 million shs1.32 million shsVERVVerve Therapeutics$11.13$9.30$2.86▼$11.40$992.13M2.233.94 million shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRUGBright Minds Biosciences0.00%-5.16%+18.83%+7.75%+2,799.14%ORICOric Pharmaceuticals0.00%-11.54%-6.04%+77.54%+4.22%PROKProKidney0.00%-14.29%+309.29%+274.35%+37.56%VERVVerve Therapeutics0.00%0.00%-0.85%+115.70%+76.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRUGBright Minds Biosciences1.648 of 5 stars3.62.00.00.00.02.50.0ORICOric Pharmaceuticals4.1497 of 5 stars3.51.00.04.42.83.30.6PROKProKidney3.272 of 5 stars3.24.00.00.03.03.30.6VERVVerve Therapeutics3.4767 of 5 stars4.24.00.00.03.22.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRUGBright Minds Biosciences 3.13Buy$83.25147.55% UpsideORICOric Pharmaceuticals 3.00Buy$18.5783.51% UpsidePROKProKidney 2.40Hold$6.25121.63% UpsideVERVVerve Therapeutics 2.33Hold$14.5730.92% UpsideCurrent Analyst Ratings BreakdownLatest DRUG, VERV, ORIC, and PROK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025PROKProKidneyUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $8.007/14/2025PROKProKidneyGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $7.007/9/2025PROKProKidneyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $9.007/8/2025ORICOric PharmaceuticalsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.007/2/2025DRUGBright Minds BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight6/30/2025PROKProKidneyBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Underperform$3.00 ➝ $1.006/27/2025VERVVerve TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$20.00 ➝ $13.506/26/2025VERVVerve TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/23/2025ORICOric PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$20.006/18/2025VERVVerve TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$28.00 ➝ $11.006/18/2025VERVVerve TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$12.00(Data available from 8/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRUGBright Minds BiosciencesN/AN/AN/AN/A$0.92 per shareN/AORICOric PharmaceuticalsN/AN/AN/AN/A$3.45 per shareN/APROKProKidney$80K10,317.68N/AN/A($3.41) per share-0.83VERVVerve Therapeutics$32.33M30.69N/AN/A$5.83 per share1.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRUGBright Minds Biosciences-$2.06M-$0.36N/AN/AN/AN/A-14.56%-14.29%8/13/2025 (Estimated)ORICOric Pharmaceuticals-$127.85M-$1.87N/AN/AN/AN/A-51.14%-46.29%8/11/2025 (Estimated)PROKProKidney-$61.19M-$0.60N/AN/AN/AN/AN/A-15.03%8/8/2025 (Estimated)VERVVerve Therapeutics-$198.71M-$2.11N/AN/AN/A-303.64%-35.81%-27.57%8/14/2025 (Estimated)Latest DRUG, VERV, ORIC, and PROK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025VERVVerve Therapeutics-$0.70N/AN/AN/A$4.26 millionN/A8/13/2025Q3 2025DRUGBright Minds Biosciences-$0.59N/AN/AN/AN/AN/A8/11/2025Q2 2025ORICOric Pharmaceuticals-$0.46N/AN/AN/AN/AN/A8/8/2025Q2 2025PROKProKidney-$0.14N/AN/AN/AN/AN/A5/15/2025Q2 2025DRUGBright Minds Biosciences-$0.39-$0.29+$0.10-$0.29N/AN/A5/14/2025Q1 2025VERVVerve Therapeutics-$0.71-$0.35+$0.36-$0.35$7.13 million$32.98 million5/12/2025Q1 2025PROKProKidney-$0.16-$0.13+$0.03-$0.13N/A$0.23 million5/5/2025Q1 2025ORICOric Pharmaceuticals-$0.51-$0.42+$0.09-$0.42N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRUGBright Minds BiosciencesN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRUGBright Minds BiosciencesN/A126.01126.01ORICOric PharmaceuticalsN/A12.0012.00PROKProKidneyN/A10.9610.96VERVVerve TherapeuticsN/A9.849.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRUGBright Minds Biosciences40.52%ORICOric Pharmaceuticals95.05%PROKProKidney51.59%VERVVerve Therapeutics97.11%Insider OwnershipCompanyInsider OwnershipDRUGBright Minds Biosciences42.66%ORICOric Pharmaceuticals5.55%PROKProKidney41.49%VERVVerve Therapeutics19.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionableORICOric Pharmaceuticals8085.22 million80.49 millionOptionablePROKProKidney3292.70 million171.26 millionOptionableVERVVerve Therapeutics11089.14 million71.94 millionOptionableDRUG, VERV, ORIC, and PROK HeadlinesRecent News About These CompaniesVerve Therapeutics Announces Merger and Nasdaq DelistingAugust 3 at 2:56 AM | theglobeandmail.comGSA Capital Partners LLP Buys 78,768 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)August 2 at 5:20 AM | marketbeat.comGene Therapy Companies Set Sights on Cardiovascular DiseaseAugust 1 at 1:15 PM | genengnews.comGY Intercept Hong Kong Ltd Takes Position in Verve Therapeutics, Inc. (NASDAQ:VERV)July 31, 2025 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Receives $14.57 Consensus Target Price from AnalystsJuly 31, 2025 | americanbankingnews.comCwm LLC Purchases 24,841 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)July 30, 2025 | marketbeat.comCerity Partners LLC Invests $110,000 in Verve Therapeutics, Inc. (NASDAQ:VERV)July 30, 2025 | marketbeat.comVerve Therapeutics (VERV) Reported Results From its Heart-2 Phase 1b Trial for VERVE-102July 29, 2025 | msn.comVerve Therapeutics, Inc. (NASDAQ:VERV) Receives Consensus Rating of "Hold" from AnalystsJuly 28, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Raised to "Hold" at Wall Street ZenJuly 28, 2025 | americanbankingnews.comEli Lilly and Company: Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular riskJuly 26, 2025 | finanznachrichten.deVerve Therapeutics (NASDAQ:VERV) Upgraded to "Hold" at Wall Street ZenJuly 26, 2025 | marketbeat.comEli Lilly completes acquisition of Verve TherapeuticsJuly 25, 2025 | msn.comLilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular riskJuly 25, 2025 | prnewswire.comLilly and Verve announce expiration of Verve tender offerJuly 24, 2025 | prnewswire.comPenn CRISPR science is the foundation for a gene-editing heart disease treatment under Eli LillyJuly 24, 2025 | msn.comEli Lilly Advances Pipeline and Gene Focus With Verve AcquisitionJuly 24, 2025 | finance.yahoo.com3 Bullish Biotech Stocks With Explosive Growth Trends...July 21, 2025 | marketbeat.comLilly’s $1 billion CRISPR bet: what Verve means for gene editingJuly 16, 2025 | thepharmaletter.comTGoldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook (VERV)...July 15, 2025 | marketbeat.comBiotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.July 14, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAmerica Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?The Meteoric Rise of Rocket Lab: A Space Stock to WatchBy Ryan Hasson | July 11, 2025View The Meteoric Rise of Rocket Lab: A Space Stock to Watch3 Bullish Biotech Stocks With Explosive Growth TrendsBy Chris Markoch | July 21, 2025View 3 Bullish Biotech Stocks With Explosive Growth TrendsChipotle: Too Spicy for Smart Money to Resist After Stock SplitBy Jeffrey Neal Johnson | July 11, 2025View Chipotle: Too Spicy for Smart Money to Resist After Stock SplitPepsiCo Bottomed Out—Time to Chugalug This Blue-Chip Buy?By Thomas Hughes | July 19, 2025View PepsiCo Bottomed Out—Time to Chugalug This Blue-Chip Buy?DRUG, VERV, ORIC, and PROK Company DescriptionsBright Minds Biosciences NASDAQ:DRUG$33.63 -0.14 (-0.41%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$33.72 +0.09 (+0.28%) As of 08/1/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Oric Pharmaceuticals NASDAQ:ORIC$10.12 +0.15 (+1.50%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.12 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.ProKidney NASDAQ:PROK$2.82 +0.05 (+1.81%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.90 +0.08 (+2.84%) As of 04:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Verve Therapeutics NASDAQ:VERV$11.13 0.00 (0.00%) As of 07/25/2025Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
